Update to Interim guidance for preexposure prophylaxis (PrEP) for the prevention of HIV infection : PrEP for injecting drug users

Smith, Dawn K.; Martin, Michael; Lansky, Amy; Mermin, Jonathan; Choopanya, Kachit

Advanced Search

Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

Advanced Search
Custom Query

All these words:

For very narrow results

This exact word or phrase:

When looking for a specific result

Any of these words:

Best used for discovery & interchangable words

None of these words:

Recommended to be used in conjunction with other fields

Language:

Dates

Publication Date Range:

to

Document Data

Title:

Document Type:

Library

Collection:

Series:

People

Author:

Clear All

Query Builder

Query box

Clear All

For additional assistance using the Custom Query please check out our Help Page

i

Update to Interim guidance for preexposure prophylaxis (PrEP) for the prevention of HIV infection : PrEP for injecting drug users

June 14, 2013
By Smith, Dawn K. ; Martin, Michael ; Lansky, Amy ; ...
Source: MMWR. Morbidity and mortality weekly report. 2013 Jun 14; 62(23):463-5

[PDF-72.62 KB]

English

Details You May Also Like

Details:

Personal Author:

Smith, Dawn K. ; Martin, Michael ; Lansky, Amy ; Mermin, Jonathan ; Choopanya, Kachit

Smith, Dawn K. ; Martin, Michael ; Lansky, Amy ; Mermin, Jonathan ; Choopanya, Kachit Less -
Corporate Authors:

Centers for Disease Control and Prevention (U.S.) ; Bangkok Tenofovir Study Group.

Centers for Disease Control and Prevention (U.S.) ; Bangkok Tenofovir Study Group. Less -
Description:

On June 12, 2013, the Thailand Ministry of Health and CDC published results from a randomized controlled trial of a daily oral dose of 300 mg of tenofovir disoproxil fumarate (TDF) that showed efficacy in reducing the acquisition of human immunodeficiency virus (HIV) infection among injecting drug users (IDUs) (1). Based on these findings, CDC recommends that preexposure prophylaxis (PrEP) be considered as one of several prevention options for persons at very high risk for HIV acquisition through the injection of illicit drugs.

PMID: 23760186
Subjects:

[+]

Adenine/analogs & Derivatives Adenine/therapeutic Use Anti-HIV Agents/therapeutic Use Deoxycytidine/analogs & Derivatives Deoxycytidine/therapeutic Use Female Heterosexuality HIV Infections/epidemiology HIV Infections/prevention & Control Homosexuality, Male Humans Male Organophosphonates/therapeutic Use Practice Guidelines As Topic Randomized Controlled Trials As Topic Risk Assessment Substance Abuse, Intravenous/epidemiology
Source:

MMWR. Morbidity and mortality weekly report. 2013 Jun 14; 62(23):463-5
Document Type:

Journal Article
Name as Subject:

Centers for Disease Control and Prevention (U.S.)
Genre:

Practice Guideline
Place as Subject:

United States
Collection(s):

Morbidity and Mortality Weekly Report (MMWR) Guidelines and Recommendations
Main Document Checksum:

[+]

urn:sha256:ff6ec3718dc1ca389ccef6175da864ab3caec5f2bc0ac3abeab9bccb0271a47d
Download URL:

https://stacks.cdc.gov/view/cdc/23107/cdc_23107_DS1.pdf
File Type:

No Additional Files

More +

Update to Interim guidance for preexposure prophylaxis (PrEP) for the prevention of HIV infection : PrEP for injecting drug users

Details:

Supporting Files

You May Also Like